Financial News Archive

SEC EDGAR · Federal Reserve · FDA · BLS · Updated every 60s

Ingenus
FDA Approves LEUCOVORIN CALCIUM — Ingenus Pharmaceuticals, LLC

# FDA Approves Ingenus Pharmaceuticals' Oral Leucovorin Calcium Generic Ingenus Pharmaceuticals, LLC has received FDA approval for oral leucovorin ca...

AstraZeneca
FDA Approves BREZTRI — AstraZeneca Pharmaceuticals LP

# FDA Approves AstraZeneca's BREZTRI for COPD Treatment AstraZeneca Pharmaceuticals LP received FDA approval for BREZTRI (budesonide, glycopyrrolate,...

BluePoint
FDA Approves IMATINIB MESYLATE — BluePoint Laboratories

# FDA Approves Generic Imatinib Mesylate by BluePoint Laboratories BluePoint Laboratories received FDA approval for its generic formulation of imatin...

Accord
FDA Approves BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Accord Healthcare, Inc

The FDA has approved a sublingual formulation of buprenorphine and naloxone hydrochloride dihydrate from Accord Healthcare, expanding access to this e...

Epic
FDA Approves OXYCODONE AND ASPIRIN — Epic Pharma, LLC

Epic Pharma, LLC received FDA approval for its ANDA040910 on July 16, 2020, to manufacture and market generic oxycodone and aspirin in oral tablets. T...

ANI
FDA Approves ACYCLOVIR — ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. announced the acceptance of its Abbreviated New Drug Application (ANDA212252) for acyclovir, a formulation intended for oral...

QUAGEN
FDA Approves Unknown Drug — QUAGEN

Quagen has secured FDA approval for its application (ANDA 204649), a move expected to enhance the company's market position by increasing generic supp...

Taiho
FDA Approves INQOVI — Taiho Pharmaceutical Co., Ltd.

# FDA Approves Taiho Pharmaceutical's INQOVI, First Oral Combination Therapy for Myelodysplastic Syndromes Taiho Pharmaceutical Co., Ltd. received FD...

PHARMOBEDIENT
FDA Approves Unknown Drug — PHARMOBEDIENT

PHARMOBEDIENT announced final FDA approval for its drug application, a regulatory milestone expected to immediately bolster the company’s competitive ...

CHARTWELL
FDA Approves Unknown Drug — CHARTWELL RX

# FDA Approves Chartwell Rx Generic Drug Application Chartwell Rx has received FDA approval for its abbreviated new drug application (ANDA 207971), e...

Genentech,
FDA Approves PHESGO — Genentech, Inc.

# FDA Approves Genentech's PHESGO as First Subcutaneous Combination HER2 Therapy Genentech's FDA approval of PHESGO (pertuzumab, trastuzumab, and hya...

UCB,
FDA Approves FINTEPLA — UCB, Inc.

# FDA Approves UCB's Fintepla (Fenfluramine) for Rare Seizure Disorder UCB, Inc. received FDA approval for Fintepla (fenfluramine) oral formulation o...

MICRO
FDA Approves Unknown Drug — MICRO LABS

Micro Labs announced the FDA's approval of its ANDA to market the generic drug, a move that likely broadens its competitive footprint in the therapeut...

ViiV
FDA Approves TIVICAY PD — ViiV Healthcare Company

ViiV Healthcare announced Tuesday the FDA approval of TIVICAY PD (dolutegravir sodium), the company's long-acting, injectable formulation of the HIV i...

VIELA
FDA Approves Unknown Drug — VIELA BIO

On June 11, 2020, VIELA BIO announced the receipt of FDA approval for a novel therapeutic, signaling the company's expansion into a new pipeline area ...

Pfizer
FDA Approves NYVEPRIA — Pfizer Laboratories Div Pfizer Inc

# FDA Approves Pfizer's NYVEPRIA, Expanding Pegfilgrastim Biosimilar Competition The FDA has approved Pfizer's NYVEPRIA (pegfilgrastim-apgf), a biosi...

AMIVAS
FDA Approves Unknown Drug — AMIVAS

# FDA Approves AMIVAS New Drug Application The FDA has approved NDA213036 for AMIVAS, marking a significant expansion of the company's product portfo...

Macleods
FDA Approves EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Macleods Pharmaceuticals Limited

Macleods Pharmaceuticals Limited received FDA approval on May 15, 2020, for the generic drug emtricitabine and tenofovir disoproxil fumarate (ANDA 203...

Eli
FDA Approves RETEVMO — Eli Lilly and Company

Eli Lilly and Company received FDA approval for RETEVMO (selmetinib) to treat patients with advanced RET-fusion-positive meningiomas, a significant mi...

CHAIN
FDA Approves MUCUS RELIEF — CHAIN DRUG MARKETING ASSOCIATION, INC.

The FDA has approved a 600 mg guaifenesin immediate-release tablet application (No. ANDA213420) for CHAIN DRUG MARKETING ASSOCIATION, INC., relieving ...